TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Biosplice Therapeutics Stock

Biosplice Therapeutics Stock

biosplice.comHealthcare / BioTech & PharmaFounded: 2008

Biosplice Therapeutics is developing therapies through alternative pre-mRNA splicing, which can allow for the elimination of harmful proteins. The company's current pipeline focuses on osteoarthritis and oncology. Biosplice Therapeutics was founded in 2008 by Osman Kibar Ph.D., Dennis Carson, Richard Schwab, and John Hood Ph.D. and is headquartered in San Diego, CA.

Buy or sell Biosplice Therapeutics stockLearn more about Biosplice Therapeutics IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Biosplice Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Biosplice Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Biosplice Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Biosplice Therapeutics investors also invested in these private companies

Vickers Venture Partners
Vast Ventures
Forepoint Capital Partners
Polar Light Ventures
aMoon Fund
SymBiosis Capital Management

Team

Management Team

Cevdet Samikoglu
Chief Executive Officer & Board Member
Erich Horsley
Chief Financial Officer & Chief Business Officer
Scott Bulcao
Chief Legal Officer
Osman Kibar Ph.D
Co-Founder & Executive Chairman
Yusuf Yazici MD
Chief Medical Officer

Board Members

Chidozie Ugwumba
SymBiosis Capital Management
Gur Roshwalb MD
aMoon Fund
Joy Ghosh Ph.D
Eventide Asset Management
Kyle Rasbach Ph.D
Eventide Asset Management

Frequently Asked Questions About Biosplice Therapeutics’ Stock

plusminus
Can you buy Biosplice Therapeutics’ stock?
Biosplice Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Biosplice Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Biosplice Therapeutics’ stock?
Yes, you can sell stock of a private company like Biosplice Therapeutics. Forge can help you sell your Biosplice Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Biosplice Therapeutics’ stock price?
Biosplice Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Biosplice Therapeutics’ private market stock price with Forge Data.
plusminus
What is Biosplice Therapeutics’ stock ticker symbol?
Biosplice Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Biosplice Therapeutics in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

Longevity Technology News 12/22/2022
Biosplice announces data from osteoarthritis clinical trial – and the initiation of new phase 3 trial
Biosplice Therapeutics, a clinical-stage biotech company pioneering first-in-class small molecule therapeutics, has announced potential structure-modifying highlights from an ongoing long-term extension study for its knee osteoarthritis (OA) drug candidate, lorecivivint.
Pharmaceutical Technology 10/31/2022
The osteoarthritis market is expected to increase to $3.8bn in 2031
The osteoarthritis (OA) market was valued at $2.5 billion in the 7MM (seven major markets) in 2021, and is expected to increase to $3.8 billion in 2031, at a compound annual growth rate (CAGR) of 4.4%.

Trending Companies

Frequently Asked Questions

Updated on: Apr 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.